2.16.840.1.113883.5.1070/static-2012-07-24: Unterschied zwischen den Versionen
ADbot (Diskussion | Beiträge) (Automated TermBot page content) |
ADbot (Diskussion | Beiträge) (Automated TermBot page content) |
||
| Zeile 20: | Zeile 20: | ||
|0-A | |0-A | ||
|_ActSubstanceAdminSubstitutionCode | |_ActSubstanceAdminSubstitutionCode | ||
| − | |[[Datei:EN-US.png]]ActSubstanceAdminSubstitutionCode | + | |[[Datei:EN-US.png]] ActSubstanceAdminSubstitutionCode |
| colspan="2" |<p>Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.</p> | | colspan="2" |<p>Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.</p> | ||
|- | |- | ||
|1-S | |1-S | ||
|'''E''' | |'''E''' | ||
| − | |[[Datei:EN-US.png]]equivalent | + | |[[Datei:EN-US.png]] equivalent |
| colspan="2" |<p>Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.</p> | | colspan="2" |<p>Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.</p> | ||
|- | |- | ||
|2-S | |2-S | ||
|'''EC''' | |'''EC''' | ||
| − | |[[Datei:EN-US.png]]equivalent composition | + | |[[Datei:EN-US.png]] equivalent composition |
| colspan="2" |<p>Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril</p> | | colspan="2" |<p>Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril</p> | ||
|- | |- | ||
|3-L | |3-L | ||
|'''BC''' | |'''BC''' | ||
| − | |[[Datei:EN-US.png]]brand composition | + | |[[Datei:EN-US.png]] brand composition |
| colspan="2" |<p>Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven</p> | | colspan="2" |<p>Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven</p> | ||
|- | |- | ||
|3-L | |3-L | ||
|'''G''' | |'''G''' | ||
| − | |[[Datei:EN-US.png]]generic composition | + | |[[Datei:EN-US.png]] generic composition |
| colspan="2" |<p>Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)</p> | | colspan="2" |<p>Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)</p> | ||
|- | |- | ||
|2-S | |2-S | ||
|'''TE''' | |'''TE''' | ||
| − | |[[Datei:EN-US.png]]therapeutic alternative | + | |[[Datei:EN-US.png]] therapeutic alternative |
| colspan="2" |<p>Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet</p> | | colspan="2" |<p>Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet</p> | ||
|- | |- | ||
|3-L | |3-L | ||
|'''TB''' | |'''TB''' | ||
| − | |[[Datei:EN-US.png]]therapeutic brand | + | |[[Datei:EN-US.png]] therapeutic brand |
| colspan="2" |<p>Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics> Examples: Zantac for Tagamet</p> | | colspan="2" |<p>Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics> Examples: Zantac for Tagamet</p> | ||
|- | |- | ||
|3-L | |3-L | ||
|'''TG''' | |'''TG''' | ||
| − | |[[Datei:EN-US.png]]therapeutic generic | + | |[[Datei:EN-US.png]] therapeutic generic |
| colspan="2" |<p>Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands> Examples: Ranitidine for cimetidine</p> | | colspan="2" |<p>Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands> Examples: Ranitidine for cimetidine</p> | ||
|- | |- | ||
|1-L | |1-L | ||
|'''F''' | |'''F''' | ||
| − | |[[Datei:EN-US.png]]formulary | + | |[[Datei:EN-US.png]] formulary |
| colspan="2" |<p>Description: This substitution was performed or is permitted based on formulary guidelines.</p> | | colspan="2" |<p>Description: This substitution was performed or is permitted based on formulary guidelines.</p> | ||
|- | |- | ||
|1-L | |1-L | ||
|'''N''' | |'''N''' | ||
| − | |[[Datei:EN-US.png]]none | + | |[[Datei:EN-US.png]] none |
| colspan="2" |<p>No substitution occurred or is permitted.</p> | | colspan="2" |<p>No substitution occurred or is permitted.</p> | ||
|} | |} | ||
Aktuelle Version vom 18. November 2012, 13:18 Uhr
| Codesystem Name | Codesystem Id | Version / Eingangsdatum | Status | |
|---|---|---|---|---|
| substanceAdminSubstitution | 2.16.840.1.113883.5.1070 | 2012-07-24 | definitiv | |
| Level/Typ | Code | Anzeigename | Beschreibung | |
| 0-A | _ActSubstanceAdminSubstitutionCode |  ActSubstanceAdminSubstitutionCode
|
Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects. | |
| 1-S | E | equivalent
|
Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product. | |
| 2-S | EC | equivalent composition
|
Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril | |
| 3-L | BC | brand composition
|
Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven | |
| 3-L | G | generic composition
|
Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp) | |
| 2-S | TE | therapeutic alternative
|
Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet | |
| 3-L | TB | therapeutic brand
|
Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics> Examples: Zantac for Tagamet | |
| 3-L | TG | therapeutic generic
|
Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands> Examples: Ranitidine for cimetidine | |
| 1-L | F | formulary
|
Description: This substitution was performed or is permitted based on formulary guidelines. | |
| 1-L | N | none
|
No substitution occurred or is permitted. | |
